Galecto Inc. (GLTO)
4.55
-2.15 (-32.09%)
At close: Mar 25, 2025, 3:49 PM
4.53
-0.49%
Pre-market: Mar 26, 2025, 07:38 AM EDT
-32.09% (1D)
| Bid | 4.3 |
| Market Cap | 6.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.56M |
| EPS (ttm) | -18.53 |
| PE Ratio (ttm) | -0.25 |
| Forward PE | -0.33 |
| Analyst | Buy |
| Ask | 4.58 |
| Volume | 608,121 |
| Avg. Volume (20D) | 239,118 |
| Open | 6.60 |
| Previous Close | 6.70 |
| Day's Range | 4.02 - 6.61 |
| 52-Week Range | 3.76 - 21.05 |
| Beta | 1.19 |
About GLTO
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a ...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 29, 2020
Employees 5
Stock Exchange NASDAQ
Ticker Symbol GLTO
Website https://galecto.com
Analyst Forecast
According to 1 analyst ratings, the average rating for GLTO stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 119.78% from the latest price.
Stock Forecasts5 months ago
-27.48%
Galecto shares shares are trading lower. The compa...
Unlock content with
Pro Subscription
